Drugs/Recall·openFDA/drug

Eugia US LLC — Class III: Lidocaine HCl Injection, USP 2%, 40 mg/2 mL (20 mg/mL), 2 mL per Single-Dose Vial, Rx Only

LowPublished Jun 10, 2026· AI-analyzed Jun 15, 2026View original FDA source
AI-generated regulatory interpretation. The four sections below are an analyst-style summary produced by an AI model from the original FDA source. Always verify against the source before any regulatory, clinical, or commercial decision.
What happened

Eugia US LLC has initiated a Class III recall for specific lots of Lidocaine HCl Injection, USP 2%, because the label wrap covers the barcode, rendering it difficult to scan.

Who it affects

This affects Eugia US LLC, healthcare providers utilizing Lidocaine HCl 2% single-dose vials, and pharmaceutical labeling and packaging departments.

Why it matters

While a Class III recall indicates the product is unlikely to cause adverse health consequences, barcode scannability issues can disrupt hospital workflows and pharmacy inventory management. This suggests a localized failure in the labeling application or design process that failed to account for barcode clearance.

Practical takeaway

Review labeling application processes for vial wraps to ensure barcode visibility is maintained; verify that secondary packaging or label placement does not interfere with scannability during QA inspections.

FDA source material

Class III. Reason: Labeling: Not Elsewhere Classified: The label wrap covers the barcode, making it hard to scan. Product: Lidocaine HCl Injection, USP 2%, 40 mg/2 mL (20 mg/mL), 2 mL per Single-Dose Vial, Rx Only, Mfd. in India for: Eugia US LLC, E. Windsor, NJ 08520. NDC: 55150-164-02. Firm: Eugia US LLC (East Windsor NJ United States). Status: Ongoing.

Open in openFDA / FDA.gov
AI-generated interpretation. Always verify critical decisions against the original FDA source. Generated with google/gemini-3-flash-preview.